WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

ATC codeATC level nameNew DDDUnitAdm.routeDeadline for objection to temporary codesImplementation in ATC/DDD index
A03FA07 itopride0.15gO01.09.20212022
A10BJ06semaglutide10.5mgOFinal2022
A16AB15velmanase alfa10mgPFinal2022
B02BX08avatrombopag20mgO01.09.20212022
B03XA06luspatercept3.33mgPFinal2022
B06AX01crizanlizumab12.5mgP01.09.20212022
C08EX02perhexiline0.2gOFinal2022
H02CA03ketoconazole0.6gO01.09.20212022
J01MA15gemifloxacin0.2gPFinal2022
J05AB16remdesivir0.1gPFinal2022
J05AG05rilpivirine15mgP01.09.20212022
J05AH01zanamivir1.2gPFinal2022
J05AJ04cabotegravir10mgP01.09.20212022
J05AJ04cabotegravir30mgO01.09.20212022
J05AX29fostemsavir1.2gO01.09.20212022
L01EA01imatinib0.4gOFinal2022
L01EA02dasatinib0.1gOFinal2022
L01EA03nilotinib0.6gOFinal2022
L01EA04bosutinib0.4gOFinal2022
L01EA05ponatinib45mgOFinal2022
L01EB01gefitinib0.25gOFinal2022
L01EB02erlotinib0.15gOFinal2022
L01EB03afatinib40mgOFinal2022
L01EB04osimertinib80mgOFinal2022
L01EB07dacomitinib45mgOFinal2022
L01EC01vemurafenib1.92gOFinal2022
L01EC02dabrafenib0.3gOFinal2022
L01EC03encorafenib0.45gOFinal2022
L01ED01crizotinib 0.5gOFinal2022
L01ED02ceritinib0.45gOFinal2022
L01ED03alectinib1.2gOFinal2022
L01ED04brigatinib0.18gOFinal2022
L01ED05lorlatinib0.1gOFinal2022
L01EE01trametinib2mgOFinal2022
L01EE02cobimetinib45mgOFinal2022
L01EE03binimetinib90mgOFinal2022
L01EF01palbociclib94mgOFinal2022
L01EF02ribociclib0.45gOFinal2022
L01EF03abemaciclib0.3gOFinal2022
L01EG01temsirolimus3.57mgPFinal2022
L01EG02everolimus10mgOFinal2022
L01EH01lapatinib1.25gOFinal2022
L01EH02neratinib0.24gOFinal2022
L01EH03tucatinib0.6gOFinal2022
L01EJ01ruxolitinib30mgOFinal2022
L01EJ02fedratinib0.4gOFinal2022
L01EK01axitinib10mgOFinal2022
L01EK03tivozanib1mgOFinal2022
L01EL01ibrutinib0.42gOFinal2022
L01EL02acalabrutinib0.2gOFinal2022
L01EL03zanubrutinib0.32gOFinal2022
L01EM01idelalisib0.3gOFinal2022
L01EM02copanlisib6.43mgOFinal2022
L01EM03alpelisib0.3gOFinal2022
L01EM04duvelisib50mgOFinal2022
L01EX01sunitinib33mgOFinal2022
L01EX02sorafenib0.8gOFinal2022
L01EX03pazopanib0.8gOFinal2022
L01EX04vandetanib0.3gOFinal2022
L01EX05regorafenib0.12gOFinal2022
L01EX07cabozantinib60mgOFinal2022
L01EX08lenvatinib18mgOFinal2022
L01EX09nintedanib0.38gOFinal2022
L01EX10midostaurin0.1gOFinal2022
L01EX12larotrectinib0.2gOFinal2022
L01EX13gilteritinib0.12gOFinal2022
L01EX14entrectinib0.6gOFinal2022
L01EX15pexidartinib0.8gOFinal2022
L01EX16erdafitinib9mgOFinal2022
L01EX17capmatinib0.8gOFinal2022
L01EX18avapritinib0.3gOFinal2022
L01EX19ripretinib0.15gOFinal2022
L01EX20pemigatinib9mgOFinal2022
L01EX22selpercatinib0.32gOFinal2022
L01EX23pralsetinib0.4g OFinal2022
L02BB06darolutamide1.2gOFinal2022
L04AA38ozanimod0.92mgOFinal2022
L04AA41imlifidase17.5mg 1)P 01.09.20212022
L04AA43ravulizumab58.9mgP01.09.20212022
L04AA44upadacitinib 15mgO01.09.20212022
N02BG11mirogabalin25mgOFinal2022
N03AX24cannabidiol0.7gOFinal2022
N05AL05amisulpride7.5mgPFinal2022
N05CF04eszopiclone2mgO01.09.20212022
N06AX27esketamine8mgNFinal2022
N06AX28levomilnacipran 40mgO01.09.20212022
R03CC15formoterol0.16mgO01.09.20212022
V03AG05sodium phosphate8gOFinal2022
1) course dose

Last updated: 2021-05-04